{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:29:00Z","timestamp":1792506540187,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2022-NR067484"],"award-info":[{"award-number":["RS-2022-NR067484"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-RS-2024-00443043"],"award-info":[{"award-number":["NRF-RS-2024-00443043"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129059","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:55:57Z","timestamp":1787259357000},"page":"129059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant"],"prefix":"10.1016","volume":"91","author":[{"given":"Seung-Ji","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Eun","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ha","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Jeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Na","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jin","family":"Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Yon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Baek","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Joon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Seuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129059_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.econmod.2023.106551","article-title":"The global economic impacts of the COVID-19 pandemic","volume":"129","author":"McKibbin","year":"2023","journal-title":"Econ Model"},{"key":"10.1016\/j.vaccine.2026.129059_bb0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0025","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129059_bb0030","article-title":"SARS-CoV-2 evolution: immune dynamics, omicron specificity, and predictive modeling in vaccinated populations","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.vaccine.2026.129059_bb0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41586-024-08477-8","article-title":"SARS-CoV-2 evolution on a dynamic immune landscape","volume":"639","author":"Raharinirina","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129059_bb0040","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/v15051109","article-title":"Virus-like particle vaccines and platforms for vaccine development","volume":"15","author":"Kheirvari","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129059_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12257-022-0107-8","article-title":"Virus-like particles as antiviral vaccine: mechanism, design, and application","volume":"28","author":"Zhang","year":"2023","journal-title":"Biotechnol Bioprocess Eng"},{"key":"10.1016\/j.vaccine.2026.129059_bb0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0055","doi-asserted-by":"crossref","first-page":"11318","DOI":"10.1128\/JVI.01052-08","article-title":"The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles","volume":"82","author":"Siu","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.04.006","article-title":"CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses","volume":"54","author":"Lineburg","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.129059_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129059_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127602","article-title":"Mucosal COVID-19 vaccines in clinical development","volume":"63","author":"Tscherne","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129059_bb0075","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1016\/j.vaccine.2023.04.013","article-title":"Promises and challenges of mucosal COVID-19 vaccines","volume":"41","author":"Rathore","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129059_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.10.040","article-title":"Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19","volume":"147","author":"Cervia","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines13111105","article-title":"Heterologous SARS-CoV-2 buccal immunization with oral dissolving films generated a strong systemic and mucosal immunity in a murine model","volume":"13","author":"Arte","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129059_bb0090","doi-asserted-by":"crossref","first-page":"45438","DOI":"10.1038\/s41598-025-28310-0","article-title":"Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity","volume":"15","author":"Kronsteiner","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129059_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/vaccines13040351","article-title":"Systemic and mucosal antibody responses to SARS-CoV-2 variant-specific prime-and-boost and prime-and-spike vaccination: a comparison of intramuscular and intranasal bivalent vaccine administration in a murine model","volume":"13","author":"Maltseva","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.129059_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01260-4","article-title":"Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity","volume":"10","author":"Yang","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129059_bb0105","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241529","article-title":"Heterologous mucosal vaccine boosting enhances mucosal and systemic immunity by distinct mechanisms","volume":"223","author":"Bissett","year":"2026","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2026.129059_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adp9279","article-title":"SARS-CoV-2 JN.1 variant evasion of IGHV3-53\/3-66 B cell germlines","volume":"9","author":"Paciello","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2022.105278","article-title":"Identification, propagation and molecular characterization of SARS-CoV-2 delta variant isolated from Egyptian COVID-19 patients","volume":"100","author":"Alotaibi","year":"2022","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2020.113995","article-title":"Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2","volume":"287","author":"Park","year":"2021","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2026.129059_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-61779-349-3_13","article-title":"Recombinant protein expression in the baculovirus-infected insect cell system","volume":"800","author":"Unger","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1743-422X-9-210","article-title":"Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media","volume":"9","author":"Lynch","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2026.129059_bb0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymeth.2005.11.007","article-title":"Western blotting","volume":"38","author":"Kurien","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2026.129059_bb0140","series-title":"Biological specimen preparation for transmission electron microscopy","author":"Glauert","year":"1998"},{"key":"10.1016\/j.vaccine.2026.129059_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2026.129059_bb0150","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1016\/j.vaccine.2023.06.080","article-title":"Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice","volume":"41","author":"Lee","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129059_bb0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-022-00451-7","article-title":"Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge","volume":"7","author":"Wong","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129059_bb0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12985-025-02760-4","article-title":"Intranasally administered whole virion inactivated vaccine against clade 2.3.4.4b H5N1 influenza virus with optimized antigen and increased cross-protection","volume":"22","author":"Song","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2026.129059_bb0165","series-title":"Theory and practice of histological techniques","year":"2008"},{"key":"10.1016\/j.vaccine.2026.129059_bb0170","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(20)31305-2","article-title":"Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington state: a case series","volume":"396","author":"Bradley","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129059_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0042-6822(03)00120-X","article-title":"Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production","volume":"310","author":"Jarvis","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.129059_bb0180","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of the SARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.129059_bb0185","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41467-022-29255-y","article-title":"Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium","volume":"13","author":"Pinto","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129059_bb0190","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57309","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"Bar-On","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.vaccine.2026.129059_bb0195","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1080\/14760584.2025.2597455","article-title":"Antigenic drift in SARS-CoV-2: diminished vaccine protection in pediatric populations against omicron and its JN.1 subvariant","volume":"24","author":"Pires Farias","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.129059_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/v17091177","article-title":"Pathogenicity of SARS-CoV-2 omicron subvariants JN.1, KP.2, and EG.5.1 in K18-hACE2 transgenic mice","volume":"17","author":"Patterson","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129059_bb0205","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129059_bb0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijbiomac.2022.01.108","article-title":"A systematic review of virus-like particles of coronavirus: assembly, generation, chimerism and their application in basic research and in the clinic","volume":"200","author":"Lu","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.129059_bb0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?","volume":"22","author":"Kent","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0225","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129059_bb0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.129059_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.129059_bb0240","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129059_bb0245","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2023.02.017","article-title":"SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses","volume":"56","author":"Koutsakos","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.129059_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2026.129059_bb0265","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.129059_bb0270","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129059_bb0275","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.129059_bb0280","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e29","article-title":"Omicron subvariants, including BA.4 and BA.5, substantially preserve T cell epitopes of ancestral SARS-CoV-2","volume":"22","author":"Park","year":"2022","journal-title":"Immune Netw"},{"key":"10.1016\/j.vaccine.2026.129059_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.129059_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.11.010","article-title":"Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study","volume":"28","author":"Chia","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2026.129059_bb0295","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.vaccine.2026.129059_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/srep33123","article-title":"Chemokine CXCL1 mediated neutrophil recruitment: role of glycosaminoglycan interactions","volume":"6","author":"Sawant","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129059_bb0305","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0310","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0315","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","article-title":"GM-CSF: from growth factor to central mediator of tissue inflammation","volume":"45","author":"Becher","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.129059_bb0320","first-page":"178","article-title":"Innate immune evasion strategies of SARS-CoV-2","volume":"21","author":"Minkoff","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0325","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/v14061247","article-title":"Characterization of SARS-CoV-2 evasion: interferon pathway and therapeutic options","volume":"14","author":"Znaidia","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129059_bb0330","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs","volume":"11","author":"Zepeda-Cervantes","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0335","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","article-title":"The roles of tertiary lymphoid structures in chronic diseases","volume":"19","author":"Sato","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.vaccine.2026.129059_bb0340","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1038\/s41467-025-60885-0","article-title":"Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication","volume":"16","author":"Lenart","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129059_bb0345","first-page":"1415","article-title":"Early elevated inflammatory markers in SARS-CoV-2 vaccinated patients are associated with reduced mortality, morbidity, and lung injury","volume":"14","author":"Khayat","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.vaccine.2026.129059_bb0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40005-020-00482-z","article-title":"Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays","volume":"50","author":"Gao","year":"2020","journal-title":"J Pharm Investig"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:31:10Z","timestamp":1790537470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":70,"alternative-id":["S0264410X26008686"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129059"}}